Abiraterone is a cytochrome CYP17(17α-hydroxylase /C17, 20-lyase) inhibitor that is hydrolyzed to produce abiraterone. Abiraterone acetate reduces testosterone production by inhibiting cytochrome CYP17. Abiraterone acetate is suitable for the treatment of metastatic castration-resistant prostate cancer (CRPC) in patients who have received previous chemotherapy containing paclitaxel (see related literature)
